0.26005.45% ( -0.0150 )
Closed: Nov 20, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -1.54, within the reasonable range, cheaper than 52.69% of the time in the past 1 years, and the industry ranks 276/607, the industry Median -1.55.
-1.54xP/E
$0.26Stock price
$-0.17Earnings per share
-1.54xP/E
Stock price$0.26Earnings per share$-0.17
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.52x
- Typical range
- -1.82x–-1.29x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.45x | 162.72% | $206.43B |
MRNAUSModerna | -27.91x | 0.44% | $77.85B |
CSLLYUSCSL Limited | -24.06x | -- | $62.05B |
NTRAUSNatera | -240.69x | 4.11% | $39.64B |
RVMDUSRevolution Medicines | -18.47x | 38.62% | $34.55B |
INSMUSInsmed | -51.20x | 74.85% | $31.01B |
ROIVUSRoivant Sciences | -81.33x | 102.68% | $28.01B |
BNTXUSBioNTech SE | -11.86x | 26.17% | $20.07B |
BBIOUSBridgebio Pharma | -25.01x | 31.00% | $14.81B |
BMRNUSBioMarin Pharma | -612.14x | 55.46% | $11.70B |
KYMRUSKymera Therapeutics | -27.44x | 8.74% | $9.59B |
SYREUSSpyre Therapeutics | -39.63x | 59.92% | $8.88B |
MDGLUSMadrigal Pharma | -56.65x | 86.62% | $8.81B |
PCVXUSVaxcyte | -7.63x | 42.32% | $8.77B |
PRAXUSPraxis Precision Medicines | -23.36x | 0.35% | $8.40B |
SMMTUSSummit Therapeutics | -9.53x | 24.09% | $7.94B |
RYTMUSRhythm Pharma | -39.28x | 51.65% | $7.79B |
ALKSUSAlkermes | -21,515.32x | 133.70% | $7.55B |
CGONUSCG oncology | -29.89x | 41.23% | $7.10B |
CYTKUSCytokinetics | -9.09x | 8.68% | $7.07B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
